A federal health advisory panel in June will reconsider safety data on GlaxoSmithKline Plc’s Avandia diabetes drug, although the British…
Read More
A federal health advisory panel in June will reconsider safety data on GlaxoSmithKline Plc’s Avandia diabetes drug, although the British…
Read More